MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.

Kronos Bio, a US-based cancer therapy spinout of Massachusetts Institute of Technology, set the terms on Monday for an initial public offering that could raise up to $185m. The company intends to issue just over 10.29 million shares priced at $16 to $18 each, having initially filed to raise up to $100m last month. If…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.